Press Releases

Press Releases

Samsung Biologics wins 2016 CMO Leadership Awards for the 3rd Consecutive Year

2016 CMO Leadership Awards

Samsung Biologics wins 2016 CMO Leadership Awards for the 3rd Consecutive Year


- Honored in Quality, Reliability, Capabilities and Compatibility categories.

SEOUL, KOREA] March 24, 2016 - Samsung Biologics, a leading global contract manufacturing organization, has received multiple CMO Leadership Awards in 2016. The company has been honored in a total of four out of five categories, including
Quality, Capabilities, Reliability and Compatibility for both Overall (big and small pharma) as well as Reliability and Compatibility for big pharma.
 
Hosted by Life Science Leader, the CMO Leadership Awards Ceremony and Reception was held at W Hotel in New York. Many Pharma and BioPharma utives and leaders were in attendance. Samsung Biologics was represented by Ms. Jenifer Wheat, Vice President of Global Business Development in celebration and to highlight the company’s successful expansion as a leading global CMO. At the Awards event, Samsung was also recognized as winner of additional Individual Attribute awards in four categories including Accessible Senior Management, State-of-the-Art, Right the First Time, and On Time Delivery.
 
Samsung Biologics, established in 2011, has provided innovative and unique services with flexibly designed facilities for cost effective production of monoclonal and recombinant drug substance and drug product. In less than five years from its inception, the company received official approval for production from the U.S. Food and Drug Administration, following successful construction and operations of Plant #1 (30,000L) and Plant #2 (150,000L) located in Incheon, South Korea. Notably, the company celebrated the groundbreaking of its third plant in December 2015 (180,000L), with a total investment of 850 billion won, which will eventually double its biologics manufacturing capacity. Once the third plant begins operation in 2018, Samsung Biologics expects to become the world’s largest biologics contract manufacturing organization with a total production capacity of 360,000 liters.
 
Samsung Biologics President & CEO Dr. TH Kim commented: “We are very pleased to receive recognition for our services from leading global pharmaceutical companies. With sustainable growth and successful installation of Quality systems, Samsung Biologics has become a preferred strategic manufacturing partner to global big pharmas. With the world’s best manufacturing facilities providing full service clinical to commercial drug substance and drug product, we will put our utmost effort to maximize customer satisfaction.”
 
"Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners," says Louis Garguilo, utive Editor, Life Science Leader magazine and OutsourcedPharma.com. "Recipients are evaluated by the utives and managers at the sponsors the CMOs have worked, in the 5 critical categories of Capabilities, Compatibility, Expertise, Quality, and Reliability. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries."

 

2016 CMO Leadership Awards

Samsung Biologics wins 2016 CMO Leadership Awards for the 3rd Consecutive Year


- Honored in Quality, Reliability, Capabilities and Compatibility categories.

SEOUL, KOREA] March 24, 2016 - Samsung Biologics, a leading global contract manufacturing organization, has received multiple CMO Leadership Awards in 2016. The company has been honored in a total of four out of five categories, including
Quality, Capabilities, Reliability and Compatibility for both Overall (big and small pharma) as well as Reliability and Compatibility for big pharma.
 
Hosted by Life Science Leader, the CMO Leadership Awards Ceremony and Reception was held at W Hotel in New York. Many Pharma and BioPharma utives and leaders were in attendance. Samsung Biologics was represented by Ms. Jenifer Wheat, Vice President of Global Business Development in celebration and to highlight the company’s successful expansion as a leading global CMO. At the Awards event, Samsung was also recognized as winner of additional Individual Attribute awards in four categories including Accessible Senior Management, State-of-the-Art, Right the First Time, and On Time Delivery.
 
Samsung Biologics, established in 2011, has provided innovative and unique services with flexibly designed facilities for cost effective production of monoclonal and recombinant drug substance and drug product. In less than five years from its inception, the company received official approval for production from the U.S. Food and Drug Administration, following successful construction and operations of Plant #1 (30,000L) and Plant #2 (150,000L) located in Incheon, South Korea. Notably, the company celebrated the groundbreaking of its third plant in December 2015 (180,000L), with a total investment of 850 billion won, which will eventually double its biologics manufacturing capacity. Once the third plant begins operation in 2018, Samsung Biologics expects to become the world’s largest biologics contract manufacturing organization with a total production capacity of 360,000 liters.
 
Samsung Biologics President & CEO Dr. TH Kim commented: “We are very pleased to receive recognition for our services from leading global pharmaceutical companies. With sustainable growth and successful installation of Quality systems, Samsung Biologics has become a preferred strategic manufacturing partner to global big pharmas. With the world’s best manufacturing facilities providing full service clinical to commercial drug substance and drug product, we will put our utmost effort to maximize customer satisfaction.”
 

"Each year, the CMO Leadership Awards recognize the success that individual drug development and manufacturing organizations have in serving the needs of their biotechnology and pharmaceutical customers and partners," says Louis Garguilo, utive Editor, Life Science Leader magazine and OutsourcedPharma.com. "Recipients are evaluated by the utives and managers at the sponsors the CMOs have worked, in the 5 critical categories of Capabilities, Compatibility, Expertise, Quality, and Reliability. An award in any of these categories adds to the distinction and reputation of CMOs within the greater drug discovery, development, manufacturing and marketing industries."

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION